SLAS Europe 2026 Exhibitor Tutorials
Exhibitor Tutorials offer a powerful platform for sponsors to engage attendees with detailed product information and technical programming.
Key:
Complete
Next
Failed
Available
Locked
HAMILTON - Building a robust automated sample prep workflow to support diverse proteomics applications: Insights from a CRO
Open to view video. | Closed captions available
Open to view video. | Closed captions available
High-throughput bottom-up proteomics requires robust and standardized sample preparation to match the speed and sensitivity of modern mass spectrometry. In their recent Analytical Chemistry publication, Biognosys introduced a fully integrated, end-to-end automated workflow that standardizes protein quantification, digestion, cleanup, normalization, and LC-MS preparation within a single autonomous process. The platform demonstrates high reproducibility, longitudinal consistency, and scalability for large compound profiling studies, including quantitative target degradation applications.
Hamilton will also provide an overview of the automation architecture that supports this workflow and outline broader capabilities for scalable LC-MS sample preparation. The session highlights how collaboration between workflow developers and automation engineers enables reliable, high-throughput proteomics.
ANALYTIK JENA - Complex targets simplified: Automated purification of native membrane proteins with lab-ready solutions
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Discover a breakthrough in the toughest challenges in drug discovery: membrane protein purification. We present a new automated workflow integrating Cube Biotech's PlateX MP™ with automated liquid handling of CyBio FeliX that turns a previously failure prone, labor intensive purification endeavor into a 3 hours walk-away standard lab routine.
The copolymer-based technology isolates membrane proteins in their native lipid environment, preserving the native 3D structure and functionality. The benchtop liquid handler CyBio FeliX helps you create the right sample format for your assay, using the buffers and reagents you need while frequently delivering multi fold higher yields compared to manual procedures.
This streamlined workflow requires only a few manual steps and can be performed by any lab technician in a standard laboratory setting - no cold room or special infrastructure needed.
Membrane protein purification is no longer limiting drug discovery. Join us and learn how to open new horizons for structural biology and drug discovery.
No registration needed. Just stop by to join!
SPT Labtech - Development a 3D high-content imaging based explorative toxicology platform for tumor and healthy colorectal patient-derived organoids
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Explorative in vitro toxicology models are important for improving early safety assessment, while traditional systems may lack physiological relevance. Patient-derived organoids (PDOs) represent a significant advancement because they mimic key clinical relevant aspects of epithelial tissue biology in a 3D environment.
This study describes the development of an explorative toxicity screening platform using colorectal PDOs obtained from both tumor and matched healthy tissues. The latter is organized into distinct stem cell and differentiated cell compartments with differing proliferative and functional roles, where stem cells maintain homeostasis and self-renewal, and differentiated cells perform specialized functions including drug uptake and barrier maintenance.
A high-throughput assay was established to assess compound-induced toxicity in GI organoids enriched for either stem cell or differentiated cell populations, alongside corresponding tumor PDOs. Using the SPT Labtech Firefly platform, an automated workflow was developed to perform organoid seeding, medium handling and compound treatments. Using the Firefly’s positive displacement dispensing heads, PDOs were seeded from cryopreservation in a 3D hydrogel and supplemented with model-specific organoid culture medium. After a 48h recovery period, a medium exchange was performed to replace the organoid culture medium with differentiation medium. Additional medium refreshes were performed 120h post seeding. A panel of 6 compounds; Afatinib, Adagrasib, DM4, DXD, Gemcitabine and Bosutinib, was used to assess toxicity in 11 PDOs and to identify changes in response compared to differentiated organoid models. The effects of compounds were visualized using high content imaging of the nuclei and F-actin cytoskeleton. Image analysis (IA) was performed to measure the change in phenotypic characteristics, including organoid and nucleus size and count, cells per organoid and organoid shape, to enable distinction between cytotoxic and cytostatic compound-induced effects.
IA identified morphological differences in PDOs between differentiated and undifferentiated states. In healthy colorectal models, differentiation was associated with a reduction in lumen size and an increase in actin cytoskeletal complexity. In contrast, colorectal tumor derived models exhibited more heterogeneous morphological alterations, likely reflecting underlying intrinsic tumor biology.
The combination of automations in liquid handling, tissue differentiation and image processing offers a framework for establishing the therapeutic window of oncology drugs associated with diarrhea and GI toxicity, that uniquely facilitates the independent evaluation of compound effects on the healthy stem cell and differentiated compartments, as well as on tumor tissues.
Future work will focus on expanding the range of indications with available Breast, Lung and Pancreatic tumor and healthy organoid pairs and increase assay throughput. This platform provides a foundation for evaluating modern therapeutics such as antibody-drug conjugates (ADC’s), PROTACs and small molecules with known high toxicity profiles.